Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis

Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis (MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients treated with this drug outside clinical trials.All MDR-TB patients who started treatment from January 1, 2011 to December...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European respiratory journal Jg. 49; H. 3
Hauptverfasser:	Guglielmetti, Lorenzo, Jaspard, Marie, Le Dû, Damien, Lachâtre, Marie, Marigot-Outtandy, Dhiba, Bernard, Christine, Veziris, Nicolas, Robert, Jérôme, Yazdanpanah, Yazdan, Caumes, Eric, Fréchet-Jachym, Mathilde
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England 01.03.2017
Schlagworte:	Adult Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Diarylquinolines - administration & dosage Diarylquinolines - adverse effects Drug-Related Side Effects and Adverse Reactions - epidemiology Female France Humans Kaplan-Meier Estimate Logistic Models Male Multivariate Analysis Mycobacterium tuberculosis Retrospective Studies Sputum - microbiology Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy
ISSN:	1399-3003, 1399-3003
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!